SCHEMBL1743962

SCHEMBL1743962

CCOC(=O)c1cc(C#CCN2CCN(C(=O)OC(C)(C)C)CC2)cc(C(=O)O)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 1/20 0.40
ATM Q13315 1/20 0.40
MMP2 P08253 1/20 0.39
MMP13 P45452 1/20 0.39
HRH2 P25021 4/20 0.37
HRH1 P35367 4/20 0.37
MAPT P10636 1/20 0.37
PKM P14618 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HPGD P15428 1/20 0.37
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
PRMT1 Q99873 1/20 0.36
ADORA1 P30542 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1743960 0.85 MMP2 (0.44) LMNAMAPK1RAB9AMMP2MMP13
SCHEMBL1744445 0.84 ACKR3 (0.39) LMNAMAPK1RAB9AATMMMP2
SCHEMBL1742601 0.81 SIGMAR1 (0.45) ATMHRH2HRH1
SCHEMBL12161035 0.80 MMP13 (0.40) LMNAMAPK1RAB9AMMP2MMP13
SCHEMBL2347589 0.77 LMNA (0.62) LMNAMAPK1RAB9AMMP2MMP13
SCHEMBL13799063 0.74 ALDH1A1 (0.36) LMNAMAPK1MAPTHPGDCHRM2
SCHEMBL31218785 0.73 LMNA (0.47) LMNAMAPK1RAB9AMMP2MMP13
SCHEMBL13799056 0.72 LMNA (0.51) LMNARAB9AMAPTHPGD
SCHEMBL5710803 0.72 RAB9A (0.65) LMNAMAPK1RAB9AMAPTHPGD
SCHEMBL26290469 0.72 LMNA (0.47) LMNAMAPK1HRH2HRH1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1981889-B1 CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE SANOFI SA (FR) 2014-01-15 EP disclosed
US-8163736-B2 Cytotoxic agents comprising new tomaymycin derivatives SANOFI-AVENTIS (FR) 2012-04-24 US disclosed
EP-2386559-A1 Cytotoxiv agents comprising new tomaymycin derivatives and their therapeutic use SANOFI (FR) 2011-11-16 EP disclosed
US-20110254808-A1 REFLECTIVE TOUCH DISPLAY PANEL AND MANUFACTURING METHOD THEREOF AU OPTRONICS CORPORATION (TW) 2011-10-20 US disclosed
EP-2371827-A1 Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use SANOFI (FR) 2011-10-05 EP disclosed
US-20090036431-A1 Cytotoxic Agents Comprising New Tomaymycin Derivatives SANOFI-AVENTIS (FR) 2009-02-05 US disclosed
EP-1981889-A1 CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE Sanofi-Aventis (FR) 2008-10-22 EP disclosed
WO-2007085930-A1 CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE SANOFI-AVENTIS (FR) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036431-A1 Cytotoxic Agents Comprising New Tomaymycin Derivatives TOMM70, TOMM34, TOMM40 LMNA 681/4885MAPK1 3159/4885RAB9A 851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.